BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12922114)

  • 1. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.
    Myc A; Kukowska-Latallo JF; Bielinska AU; Cao P; Myc PP; Janczak K; Sturm TR; Grabinski MS; Landers JJ; Young KS; Chang J; Hamouda T; Olszewski MA; Baker JR
    Vaccine; 2003 Sep; 21(25-26):3801-14. PubMed ID: 12922114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model.
    Hamouda T; Chepurnov A; Mank N; Knowlton J; Chepurnova T; Myc A; Sutcliffe J; Baker JR
    Hum Vaccin; 2010 Jul; 6(7):585-94. PubMed ID: 20421727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.
    Das SC; Hatta M; Wilker PR; Myc A; Hamouda T; Neumann G; Baker JR; Kawaoka Y
    Vaccine; 2012 Nov; 30(48):6871-7. PubMed ID: 22989689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
    Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
    Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
    Takada A; Matsushita S; Ninomiya A; Kawaoka Y; Kida H
    Vaccine; 2003 Jul; 21(23):3212-8. PubMed ID: 12804850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection.
    Lai CH; Tang N; Jan JT; Huang MH; Lu CY; Chiang BL; Huang LM; Wu SC
    Vaccine; 2015 Aug; 33(35):4321-9. PubMed ID: 25858857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
    Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
    J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.
    Kang SM; Guo L; Yao Q; Skountzou I; Compans RW
    J Virol; 2004 Sep; 78(18):9624-32. PubMed ID: 15331695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
    Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
    Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protollin: a novel adjuvant for intranasal vaccines.
    Jones T; Cyr S; Allard F; Bellerose N; Lowell GH; Burt DS
    Vaccine; 2004 Sep; 22(27-28):3691-7. PubMed ID: 15315848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.
    Dhakal S; Renu S; Ghimire S; Shaan Lakshmanappa Y; Hogshead BT; Feliciano-Ruiz N; Lu F; HogenEsch H; Krakowka S; Lee CW; Renukaradhya GJ
    Front Immunol; 2018; 9():934. PubMed ID: 29770135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.
    Jones T; Allard F; Cyr SL; Tran SP; Plante M; Gauthier J; Bellerose N; Lowell GH; Burt DS
    Vaccine; 2003 Sep; 21(25-26):3706-12. PubMed ID: 12922101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccine.
    Chen KS; Burlington DB; Quinnan GV
    J Virol; 1987 Jul; 61(7):2150-4. PubMed ID: 3586130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.